- European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly and Co's (NYSE: LLY) bamlanivimab alone, and bamlanivimab plus etesevimab, in COVID-19 in patients.
- The opinion covers the COVID-19 antibody therapy for patients aged 12 years and older who do not require supplemental oxygen and are at high risk of progressing to severe COVID-19.
- In February, the antibody therapy received FDA Emergency Use Approval.
- Recently, the U.S. government agreed to purchase a minimum of 100,000 doses of antibody therapy, in an agreement valued at $210 million.
- Price Action: LLY shares increased 1.9% at $204.32 in market trading hours on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
